GENE ONLINE|News &
Opinion
Blog

Biomarin Pharmaceuticals
Will Breakthrough Therapy Lead the Way? An Overview of the Approved Gene and Cell Therapies for 2022
2023-01-13
FDA Accepts Resubmission of BioMarin’s Gene Therapy Two Years After Rejection
2022-10-13
Homology Medicines Joins Biomarin in Gene Therapy Clinical Hold
2022-02-22
ARM 2022: Industry Briefs on Cell and Gene Therapies
2022-01-17
BioMarin’s Dwarfism Drug Garners FDA Nod Amidst Concerns Over Threat to Dwarf Pride
2021-11-21
The Transformative Potential of Gene Therapies for Hemophilia
2021-04-08
R&D
BioMarin Collaborates with Canadian Biotech for AI-based Drug Discovery
2020-11-22
FDA Rejects BioMarin Pharmaceuticals’ Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-20
LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top